These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1802984)

  • 21. Report on survey of current practice employed for sterility test sampling of aseptically filled products.
    Dilloway KP; Akers JP
    J Parenter Sci Technol; 1987; 41(6):207-9. PubMed ID: 3437370
    [No Abstract]   [Full Text] [Related]  

  • 22. Aseptic processing of non-preserved parenterals.
    Avallone HL
    J Parenter Sci Technol; 1989; 43(3):113. PubMed ID: 2732849
    [No Abstract]   [Full Text] [Related]  

  • 23. Method for testing aseptic technique of intravenous admixture personnel.
    Dirks I; Smith FM; Furtado D; White SJ; Godwin HN
    Am J Hosp Pharm; 1982 Mar; 39(3):457-9. PubMed ID: 7041641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current practice in the operation and validation of aseptic blow-fill-seal processes.
    Ljungqvist B; Reinmüller B; Löfgren A; Dewhurst E
    PDA J Pharm Sci Technol; 2006; 60(4):254-8. PubMed ID: 17089694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation and routine operation of a sterile dry powder filling facility.
    Prout G
    J Parenter Sci Technol; 1982; 36(5):199-204. PubMed ID: 6927748
    [No Abstract]   [Full Text] [Related]  

  • 26. Improved aseptic technique can reduce variable contamination rates of ward-prepared parenteral doses.
    Austin P; Elia M
    J Hosp Infect; 2013 Feb; 83(2):160-3. PubMed ID: 23313030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Education and training of personnel in the clean rooms. Examination from the viewpoint of the microbiologist].
    Zuger A
    Swiss Dent; 1983; 4(1-2):27-8, 29-30, 33-5. PubMed ID: 6408766
    [No Abstract]   [Full Text] [Related]  

  • 28. Survey of manufacturers and developers of cell culture-derived products for evidence of adventitious contamination.
    Lubiniecki AS
    Dev Biol Stand; 1996; 88():195-7. PubMed ID: 9119136
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmaceutical GMPs.
    Bobrowicz G
    Qual Assur; 1994 Jun; 3(2):138-48. PubMed ID: 7804629
    [No Abstract]   [Full Text] [Related]  

  • 30. GMP and quality trends in Europe.
    Sharp J
    J Parenter Sci Technol; 1990; 44(6):296-9. PubMed ID: 2277315
    [No Abstract]   [Full Text] [Related]  

  • 31. Current and future issues in the manufacturing and development of monoclonal antibodies.
    Kozlowski S; Swann P
    Adv Drug Deliv Rev; 2006 Aug; 58(5-6):707-22. PubMed ID: 16828921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection breadth and limits for potential adventitious/endogenous contaminants in biopharmaceutical processes: a reality check for innovative methods.
    Duncan P; McKerral L; Feng S; Tsai PK
    Dev Biol (Basel); 2006; 126():283-90; discussion 327. PubMed ID: 17058504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methodology for worker neutron exposure evaluation in the PDCF facility design.
    Scherpelz RI; Traub RJ; Pryor KH
    Radiat Prot Dosimetry; 2004; 110(1-4):725-9. PubMed ID: 15353738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mayo Clinic approaches to meet United States Pharmacopeia <797> requirements for facility design and environmental controls of nuclear pharmacy.
    Hung JC; Anderson MM
    J Nucl Med; 2009 Jan; 50(1):156-64. PubMed ID: 19091891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. North American approach to smoke management.
    Klote JH
    Health Estate; 1999 Mar; 53(2):6-12. PubMed ID: 10351639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What's happened to aseptic discipline in the OR?
    Laufman H
    Todays OR Nurse; 1990 Oct; 12(10):15-9. PubMed ID: 2238020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aseptic processing and terminal sterilization. Parenteral Drug Association.
    J Parenter Sci Technol; 1991; 45(6):254-8. PubMed ID: 1802979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Science based aseptic processing.
    Akers JE
    PDA J Pharm Sci Technol; 2002; 56(6):283-90. PubMed ID: 12497765
    [No Abstract]   [Full Text] [Related]  

  • 40. Design rules and impact assessment for source control measures based on continuous long-term simulations.
    Vaes G; Berlamont J
    Water Sci Technol; 2002; 45(7):21-9. PubMed ID: 11989889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.